Carbon

Strong

Gains

<div class="textg" style="text-align: justify; font-weight: lighter; line-height: 1.3em; font-size: 15px; border-radius: 3px; color: #80909a; padding: 10px; background-color: #F4F6F9; margin-bottom: 15px;">
 Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our&nbsp;<a href="https://tokenist.com/terms-of-service/" style="text-decoration:underline;color:#3c7b7b" target="_blank" rel="noopener noreferrer nofollow">website policy</a>&nbsp;prior to making financial decisions.
</div>
<p>As markets rotate between short-term narratives, longer-duration opportunities tied to structural shifts are often overlooked. The following companies offer targeted exposure into 2026, spanning enterprise AI monetization, next-generation oncology and regulation-backed energy transformation.</p>
<h3 id="microsoft-nasdaq-msft-29-6-upside-potential">Microsoft (NASDAQ: MSFT) – 29.6% Upside Potential</h3>
<p>We recently explained in detail <a href="https://tokenist.com/msft-vrs-goog-which-stock-will-cross-the-4-trillion-milestone-first/" rel="noopener noreferrer nofollow">why Microsoft is suffering reputational damage</a> due to its Windows 11 deployment. At the same time, we also warned these concerns belong in the realm of hyperreality that comes along with social media content.</p>
<p>In actuality, the Copilot AI feature, alongside future AI refinements, are a massive boon for the company’s bottom line. Because MS Office is entrenched in the enterprise sector, organizations will increasingly demand AI-powered productivity boost. In that sense, Windows 11 is moving beyond a simple OS and serving as a vehicle for Microsoft 365 and Copilot subscriptions.</p>
<p>This is already evident by Microsoft’s Intelligent Cloud growth by 28% YoY in Q3 to $30.9 billion, with Productivity and Business Processes segment expanding by 17% to $33 billion. More importantly, as an IT wedge of the U.S. hegemony, Microsoft enjoys a unique blend of regulatory alignment, government contracts and ecosystem lock-in that few global peers can realistically challenge.</p>
<p>Although <a href="https://tokenist.com/alphabets-paradox-why-googles-decay-strengthens-its-dominance/" rel="noopener noreferrer nofollow">Alphabet (GOOGL)</a> holds similar properties and is aiming in the same direction, Microsoft’s advantage in enterprise capture is likely to grow even further. The launchpad for this further entrenchment comes from Azure’s deep integration with OpenAI models and Copilot’s monetization across Office, GitHub and Windows.</p>
<p>Presently priced at $488.02, MSFT stock is below the bottom target price of $500 per share. The Wall Street Journal’s average target places MSFT at $630.33, making for a 29.6% upside potential in the coming year.</p>
<div class="cta-referral">
 <img src="https://tokenist.com/wp-content/themes/thetokenist/assets/img/del/cta-referral-1.png" alt="" loading="lazy">
 <div class="cta-referral__text">
  <p>Join our <a href="https://t.me/thetokenist" target="_blank" rel="noopener noreferrer nofollow">Telegram group</a> and never miss a breaking digital asset story.</p>
 </div>
</div>
<h3 id="tango-therapeutics-inc-nasdaq-tngx-51-7-upside-potential">Tango Therapeutics Inc. (NASDAQ: TNGX) – 51.7% Upside Potential</h3>
<p>Exposure to this clinical-stage biotech firm is a bet on more effective cancer treatments. In particular, the company approaches cancer from a “synthetic lethality” angle, by targeting cells that already have a missing tumor suppressor gene. As healthy cells don’t have this exploit – by virtue of them being non-tumorous – targeting such cells leaves the healthy ones completely untouched.</p>
<p>Tango uses CRISPR gene editing technology for target discovery instead of treatment. Specifically, to scan for thousands of genes that have these exploits to enact synthetic lethality. For the purpose of cutting the cells’ proverbial second leg – the gene critical only to cancer cells – Tango has multiple candidates.</p>
<p>Targeting cancers missing the MTAP gene, typically found in pancreatic, glioblastoma and lung cancers, TNG462 and TNG456 are Tango’s most prospective pipeline leads. As of late October, they showed Objective Response Rate (ORR) of 27% and Disease Control Rate (DCR) of 78%, indicating significant tumor shrinkage.</p>
<p>By deploying Merck’s Keytruda (pembrolizumab), Tango is also investigating TNG260 as a selective CoREST complex inhibitor, targeting cancers with STK11 mutations that become invisible to the immune system. Tango selected TNG260 to unmask this critical advantage.</p>
<p>During the ongoing Phase I/II trial as of early October, Tango has reached the milestone of announcing its first clinical data after the trial moved into the dose expansion phase. To further support its efforts in precision cancer treatment, Tango Therapeutics announced $225 million financing in late October.</p>
<p>Presently priced at $8.70, TNGX stock is below its bottom price target of $11 per share. The Wall Street Journal’s forecasting data places the average TNGX price target at $13.25, making for a 51.7% potential upside.</p>
<h3 id="california-resources-corp-nyse-crc-45-8-upside-potential">California Resources Corp. (NYSE: CRC) – 45.8% Upside Potential</h3>
<p>Operating exclusively in California, CRC takes advantage of the state’s heavy regulatory burdens. Instead of fighting the environment-oriented regulations, CRC is monetizing them as a producer of crude oil, natural gas and natural gas liquids.</p>
<p>Through its subsidiary Carbon TerraVault (CTV), the company is aiming to capture carbon dioxide (CO2) from industrial emitters, such as power plants or cement factories. For that purpose, CRC is utilizing depleted oil reservoirs across California.</p>
<p>In accordance with government tax credits like 45Q or LCFS, CRC can then charge large industrial entities a fee to take their CO2 and bury it underground. This clever business model is turning CRC into a growth stock, as evidenced by its price targets.</p>
<p>Presently priced at $44.04, CRC stock is below the bottom price target of $51 per share. The Wall Street Journal’s forecasting data places the average CRC price target at $64.57, making for a 45.8% potential upside.</p>
<p><em>Disclaimer: The author does not hold or have a position in any securities discussed in the article.</em> <em>All stock prices were quoted at the time of writing.</em></p>
<p>The post <a rel="noopener noreferrer nofollow" href="https://tokenist.com/3-stocks-with-strong-upside-potential-for-2026-gains/">3 Stocks With Strong Upside Potential for 2026 Gains</a> appeared first on <a rel="noopener noreferrer nofollow" href="https://tokenist.com">Tokenist</a>.</p>

3 Stocks With Strong Upside Potential for 2026 Gains

Table of Contents

Tokenist

Other articles published on Dec 25, 2025

Join our free newsletter for daily crypto updates!